Surf Bio, a Palo Alto, CA-based biopharmaceutical company commercializing a novel drug stabilization platform, has received a $1.6M grant from the Bill & Melinda Gates Foundation.
The company intends to use the amount to evaluate the use of its lead technology toward increasing the thermostability and deliverability of a monoclonal antibody in low- and middle-income countries.
Led by CEO Bryan Mazlish, Surf Bio is a preclinical biopharmaceutical company that is leveraging a novel biotechnology platform to develop enhanced therapeutic solutions for oncology, autoimmune diseases, infectious diseases, gene therapy, and other therapeutic areas. It provides novel polymer technology that enables the formulation of biologics at higher concentrations and in a more thermostable form than is currently available.
Commenting on the news, Bryan Mazlish said: “We are thrilled to receive support from the Bill & Melinda Gates Foundation to advance the use of our technology to enable greater access to biologics in low- and middle-income countries.”
FinSMEs
30/04/2024